Pioglitazone and Losartan Provides Additional Renoprotection
NCT ID: NCT00364988
Last Updated: 2014-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2005-01-31
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy
NCT00361023
Renoprotection in Early Diabetic Nephropathy in Pima Indians
NCT00340678
Adiponectin and Insulin Resistance in Diabetic Nephropathy
NCT00774904
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
NCT00308347
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
NCT04238702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pioglitazone+losartan
Pioglitazone (30 mg/daily) losartan (100 mg daily)
losartan
losartan (100 mg daily)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2h plasma glucose level of 7.5-13 mmol/L
* serum creatinine values between 190 and 660umol/L
* Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is \>150mg
* Informed consent
Exclusion Criteria
* abnormal liver function
* heart dysfunction
32 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hui Min Jin
Chief,department of Nephrology,shanghai No.3 people's hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hui M Jin, MD
Role: PRINCIPAL_INVESTIGATOR
Shanghai No.3 People's Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PLAN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.